Companies › Newish Biotech (Wuxi)
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NWRD08 HPV-16/HPV-18 therapeutic vaccine (plasmid DNA) | – | Phase 2 | High-grade Squamous Intraepithelial Lesion (HSIL) | May 2027 |
| NWRD09 HPV-16 targeted mRNA therapeutic vaccine | – | Phase 1 | Persistent HPV16 Infection; High-grade Squamous Intraepithelial Lesion (HSIL) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07710664 | NWRD09 | Phase 1 | Persistent HPV16 Infection | Infectious disease | Dec 2026 |
| NCT07047989 | NWRD09 | Phase 1 | High-grade Squamous Intraepithelial Lesion (HSIL) | Oncology | Dec 2026 |
| NCT07175662 | NWRD08 | Phase 2 | High-grade Squamous Intraepithelial Lesion (HSIL) | Oncology | May 2027 |
No annotated target.
–
ImmuneOncia Therapeutics Huahui Health Tianjin ConjuStar Biologics Lantheus Medical Imaging Zhejiang Hisun Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.